Drugs / HS-10522
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07609875 | Jun 2026 → Jan 2027 expected | hypertensive disorder | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10522 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07609875 ↗ |
| Route | Oral | “HS-10522 tablet, oral, single ascending dose and multiple ascending dose, once daily” NCT07609875 ↗ |